Monday, September 5, 2016

DNA-binding protein CHD1 could be potential biomarker for targeted prostate cancer treatment

… frequently mutated genes in prostate tumors, sensitizes human prostate cancer cells to different drugs … mutated in 15-27% of all prostate tumors, and such mutations correlate with … cancer cells with other mutations in the HR repair pathway, CHD1-depleted prostate cancer

No comments:

Post a Comment